ABVC BIOPHARMA INC (ABVC) Stock Price, Quote, News and Overview
NASDAQ:ABVC - Nasdaq - US00091F3047 - Common Stock - Currency: USD
ABVC Quote, Performance and Key Statistics
1.05
+0.02 (+1.94%)
The current stock price of ABVC is 1.05 USD. In the past month the price increased by 14.82%. In the past year, price decreased by -2.78%.
ABVC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About ABVC
Company Profile
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 16 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. The company has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The firm develops drugs and medical devices derived from plants.
Company Info
ABVC BIOPHARMA INC
44370 Old Warm Springs Blvd
Fremont CALIFORNIA US
CEO: Howard Doong
Employees: 18
Phone: 15106680881
ABVC BIOPHARMA INC / ABVC FAQ
What is the stock price of ABVC BIOPHARMA INC today?
The current stock price of ABVC is 1.05 USD. The price increased by 1.94% in the last trading session.
What is the ticker symbol for ABVC BIOPHARMA INC stock?
The exchange symbol of ABVC BIOPHARMA INC is ABVC and it is listed on the Nasdaq exchange.
On which exchange is ABVC stock listed?
ABVC stock is listed on the Nasdaq exchange.
What is ABVC BIOPHARMA INC worth?
ABVC BIOPHARMA INC (ABVC) has a market capitalization of 16.57M USD. This makes ABVC a Nano Cap stock.
How many employees does ABVC BIOPHARMA INC have?
ABVC BIOPHARMA INC (ABVC) currently has 18 employees.
What are the support and resistance levels for ABVC BIOPHARMA INC (ABVC) stock?
ABVC BIOPHARMA INC (ABVC) has a support level at 0.9 and a resistance level at 1.06. Check the full technical report for a detailed analysis of ABVC support and resistance levels.
Is ABVC BIOPHARMA INC (ABVC) expected to grow?
The Revenue of ABVC BIOPHARMA INC (ABVC) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ABVC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABVC BIOPHARMA INC (ABVC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABVC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABVC, evaluating the profitability, health, valuation and growth aspects
- ABVC BIOPHARMA INC (ABVC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABVC BIOPHARMA INC (ABVC) Sales and EPS estimates to see what analysts future expectations are.
- ABVC BIOPHARMA INC (ABVC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABVC BIOPHARMA INC (ABVC) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABVC BIOPHARMA INC (ABVC) Stock Chart to make your own analysis
- ABVC BIOPHARMA INC (ABVC) Latest news and press-releases to stay up to date.
Does ABVC BIOPHARMA INC (ABVC) stock pay dividends?
ABVC does not pay a dividend.
When does ABVC BIOPHARMA INC (ABVC) report earnings?
ABVC BIOPHARMA INC (ABVC) will report earnings on 2025-05-15.
What is the Price/Earnings (PE) ratio of ABVC BIOPHARMA INC (ABVC)?
ABVC BIOPHARMA INC (ABVC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.97).
What is the Short Interest ratio of ABVC BIOPHARMA INC (ABVC) stock?
The outstanding short interest for ABVC BIOPHARMA INC (ABVC) is 1.97% of its float. Check the ownership tab for more information on the ABVC short interest.
ABVC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ABVC. When comparing the yearly performance of all stocks, ABVC is one of the better performing stocks in the market, outperforming 96.36% of all stocks.
ABVC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ABVC. ABVC may be in some trouble as it scores bad on both profitability and health.
ABVC Financial Highlights
Over the last trailing twelve months ABVC reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS increased by 72.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57% | ||
| ROE | -98.62% | ||
| Debt/Equity | 0.1 |
ABVC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ABVC. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -57.14% and a revenue growth -100% for ABVC